Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Emibetuzumab + Ramucirumab||Phase Ib/II||Actionable||In a Phase Ib/II trial, Emibetuzumab (LY2875358) and Cyramza (ramucirumab) combination treatment resulted in an objective response rate of 7% (1/15) and a disease control rate of 87% (13/15) in patients with non-small cell lung cancer, with a median progression-free survival of 6.6 months (PMID: 31142504; NCT02082210).||31142504|